IMMH-010 maleate is a prodrug that acts as a novel PD-L1 inhibitor, showing potential antitumor activity. It is being investigated for the treatment of neurological disorders and advanced malignant solid tumors. Upon oral administration, it quickly converts into its active form, YPD-29B. This compound is significant for advancing research in the field of PD-L1 inhibitors and related therapeutic applications.
- Acts as a novel PD-L1 inhibitor
- Shows potential antitumor activity
- Investigated for neurological disorders and advanced malignant solid tumors
- Converts into active form, YPD-29B, upon oral administration
- Advances research in PD-L1 inhibitors and related therapeutic applications